








































Quality control for cellular therapeutics  
 
There is growing interest in transplantation of ex vivo 
amplified cell preparations for various therapeutic 
applications. This has been fueled by novel insights 
from stem cell biology, new molecular tools and 
promising preclinical model systems. Mesenchymal 
stromal cells (MSC) can be isolated from various tissues 
including bone marrow and adipose tissue, which 
contain a rare population of adult stem cells 
(mesenchymal stem cells) with multilineage 
differentiation potential towards at least adipogenic, 











































are tested for a wide spectrum of diseases taking into 
account their paracrine effect, immunomodulatory 
activity and differentiation potential [4]. Hence, the use 
of MSC as cellular therapeutics necessitates stan-
dardized isolation and reliable quality control of cell 
preparations. This, however, is greatly hampered by the 
multitude of different methods to prepare MSC [5]. 
Furthermore, there is a growing perception that even 
under highly standardized culture conditions, 
continuous effects during long-term culture and 
eventually replicative senescence need to be taken into 
account [6,7]. 
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before they reach a senescent state. This so called 
“Hayflick limit” is commonly observed in all primary 
cell isolates [8]. Senescent cells are mitotically arrested, 
thus are not dead, and remain metabolically active. 
However due to acquired functional and molecular 
changes, MSC increase in size, they adopt “fried egg 
morphology”, expression of specific surface markers is 
attenuated [1] and adipogenic and osteogenic 
differentiation potential is affected [9-13]. Recently, we 
have demonstrated, that long-term culture is also 
associated with continuous changes in the global gene 
expression profile [1] (Figure 1). Genes involved in cell 
cycle, DNA replication, mitosis and DNA repair are 
significantly down-regulated in late passages. This 
reproducible pattern of senescence associated gene 
expression changes strengthens the hypothesis that 
cellular aging is driven by an organized process rather 
than a random accumulation of cellular defects [14]. 
Interestingly, long-term culture associated gene 
expression changes were related to age-associated 
changes in MSC from young versus elderly donors [15]. 
This indicates that cellular aging might be related to 
aging of the organism. The underlying molecular 
mechanisms of replicative senescence are still unraveled 
but it evidently has consequences for cellular therapy 
[6,16]. However, it is not a trivial question how to track 
cellular aging of MSC. 
 
Restrictions of passage numbers and population 
doublings 
 
Cells in culture can be continuously observed and 
hence, it appears straightforward to determine 
proliferation and the number of cell divisions. 
Obviously, the most convenient parameter for 
documentation of long-term culture is simply counting 
the number of cell passages. Under standardized culture 
conditions this procedure provides a predictive indicator 
for replicative senescence. However, as seeding 
densities often greatly vary between different 
laboratories (10 to 10
4 cells/cm
2) and also confluence at 
the time of harvesting [5,6,17,18], the sole recording of 
passage numbers may lead to deceptive results in order 
to compare the state of senescence under non-
standardized conditions. In this respect, calculation of 
the number of cumulative population doublings (PD) is 
more accurate [19]. MSC cultures are usually isolated 
by plastic adherent growth and hence, the initial MSC 
number can only be estimated by accounting 
fibroblastoid colony-forming unit (CFU-F) frequency 
based on the assumption that every colony has been 
derived from a single clonogenic MSC. Thereafter, cell 
numbers have to be exactly determined at all 


































Figure  1.  Continuous  gene‐expression  changes  in  MSC 
upon  long‐term  culture.  MSC  from  human  bone  marrow
were  expanded  for  11  passages  and  analyzed  by  Affymetrix 
GeneChip technology. Differential gene expression was always 
determined  versus  P2.  Hierarchical  cluster  analysis  of  all 
expressed  genes  (19,448  ESTs)  revealed  continuous  changes 
with higher passages. Hence, molecular changes in replicative 




over to the next passage and falsify PD. Yet, analysis of 
PD excludes the likely events of cells undergoing 
apoptosis, necrosis or loss during passaging. More 
importantly, there are big variations between different 
donor samples. Taken together, it is hard to predict at 
which passage or number of cell divisions MSC are 
approaching either a replicative or stress-induced 
senescent state. 
 
Surface molecules and histochemical markers for 
senescence 
 
To date no specific molecular marker is available that 
prospectively reflects the degree of cellular aging in 
MSC. For instance the leptin receptor (CD295) 
increases with higher passages under hyperoxic culture 
conditions in MSC of elderly donors [20]. Flow 
cytometric analysis of this surface marker discriminates 
a CD295-positive subpopulation, but these cells also 
stained positive for annexin V. CD295 therefore stains 
apoptotic cells that accumulate at higher passages rather 
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enlarged senescent cells based on the accumulation of 
senescence-associated beta galactosidase (SA-β-gal). 
This lysosomal protein is predominantly active in 
senescent fibroblasts and also, albeit to a lower extent, 
in MSC [21]. The staining procedure is easy and reliable 

















































sively the very large senescent cells exhibiting a “fried 
egg morphology” stain positive for SA-β-gal [1,22]. It 
should be mentioned, that SA-β-gal itself is neither 
required nor causative for manifestation of senescence 
[23]. Despite limitations in quantification and 
prospective analysis of MSC, SA-β-gal is the most 



















































Method Advantage  Disadvantage 
Number of passages  •  Counting of passages can be easily 
documented. 
•  Under standardized culture conditions 
it provides an indicator for long-term 
culture. 
•  Seeding density and expansion techniques 
vary between different laboratories. 
•  Even under standardized conditions there 
is variation between different probes. 
Cumulative  
population doublings 
•  PD can be calculated based on precise 
cell numbers at every passage and 
exact seeding densities. 
•  This parameter is more robust for 
comparison between different 
laboratories. 
•  The initial CFU-F frequency is required to 
estimate initial PD. 
•  MSC are heterogeneous and the number 
of PD does not correspond to the number 
of cell divisions in individual cells. 
•  Prospective information on the senescent 
state is hampered by large variation 
between different samples. 
SA-β-galactosidase   •  Fast and easy method to stain activity 
of lysosomal, senescence associated 
beta-galactosidase. 
•  SA-β gal is over-expressed and 
accumulates specifically in senescent 
cells. 
•  SA-β-gal is not required for senescence. 
•  Especially the large cells become beta-gal 
positive. 
•  Quantitative analysis for quality control is 
difficult. 
Karyotype /  
array-CGH  
•  May detect mutations and potentially 
immortalized cell clones. 
•  Might prevent transplant-associated 
tumor formation. 
•  Human MSC appear to be relatively stable 
for karyotypic aberrations. 
•  No marker for normal cellular aging.  
Telomere length  •  Might provide a direct measure for 
prospective analysis of potential cell 
divisions. 
•  Several techniques are available to 
quantify telomere length. 
•  Stress induced senescence might be 
independent of cell cycle and telomere 
shortening. 
•  It is yet unclear if analysis of telomere 
length facilitates reliable quality control in 
different MSC preparations. 
Gene expression 
markers 
•  RT-PCR and microarray techniques 
facilitate fast and reliable 
quantification. 
•  A panel of up-regulated and down-
regulated genes may be more robust 
than individual markers. 
•  Differential gene expression needs to be 
normalized to “house keeping genes”. 
•  Suitable gene-sets need to be established 
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Clinical trials with MSC usually employ 1-2 x 10
6 MSC 
per kg bodyweight for transplantation and therefore 
large-scale expansion is an indispensable prerequisite. 
Proliferation under non-physiologic in vitro culture 
conditions can result in mutations and chromosomal 
aberrations and eventually leads to malignant 
transformations. Karyotypic aberrations are commonly 
observed in MSC from mice and rats [24-26] whereas 
they have only been examined in few studies with human 
MSC [27-29]. So far tumor formation has not been 
described in clinical trials with MSC. Malignant 
transformation is obviously the “sword of Damocles” 
hovering above therapeutic cell products. The risk can be 
reduced by conventional karyotyping of MSC, however, 
minor genomic gains or losses may not be detected. 
Array complete genomic hybridization (CGH) analysis is 
more sensitive but this technique is incapable of 
revealing balanced translocations or very small 
mutations. Furthermore, malignant transformation may 
involve over-expression of c-myc, activation of cyclin 
dependent kinases, deletion of tumor suppressor genes 
such as p16
ink4a, RB or p53 and re-expression of 
telomerase [30]. Initially, these changes may only occur 
in a small subset of cell preparations. At that point, it 
remains to be demonstrated whether routine karyotype 
analysis does actually reduce the risk of transplant-related 
tumor formation. It is however generally accepted that 
the stochastic effects of malignant transformation are no 
suitable markers in order to determine normal 




MSC do not express telomerase and therefore telomere 
length decreases approximately 50-200 nucleotides per 
cell cycle [31] and there is evidence, that telomere 
shortening occurs also upon aging in vivo [33]. Ectopic 
expression of telomerase can immortalize MSC while 
their differentiation potential is maintained [32]. It is 
still under debate, if telomere loss really plays a causal 
role for replicative senescence or aging. Either way, loss 
of telomere length might facilitate some kind of internal 
clock to assess the state of cellular aging. Various 
methods are available to determine telomere length 
including Southern hybridization, flow cytometry based 
methods or quantitative PCR [34]. Therefore, telomere 
length may serve as another good indicator for mitotic 
history and the prospective additional life span. 
However, stress induced senescence may occur 
independent of cell division and it needs to be 
demonstrated if quantitative analysis of telomere length 
facilitates reliable and prospective quality control with 









































Figure  2.  Gene  expression  markers  for  replicative
senescence.  MSC  from  human  bone  marrow  were  either
culture expanded as described before in medium–M1 with 2%
fetal calf serum (M1, in Heidelberg, Germany [1]; n=3), in culture
medium  with  10%  fetal  calf  serum  (FCS,  n=2)  or  10%  pooled
human platelet lysate (pHPL, n=2; both in Graz, Austria [38]), in
MEM supplemented with 20% FCS (Innsbruck, Austria [40]; n=2),
and  in  MSCGM  (Lonza)  culture  medium  (Rostock,  Germany;
n=4).  Furthermore,  MSC  from  adipose  tissue  were  expanded
with 10% pHPL (Aachen, Germany, n=4). RNA was isolated from








Senescence markers on gene expression level 
 
Long-term culture induces continuous changes in gene 
expression [1]. A clear-cut characterization of distinct 
aberrations might facilitate determination when cells are 
shifting into the final state of senescence. A prerequisite 
is the reproducibility of senescence-associated gene 
expression changes in different MSC preparations, 
whereas techniques for cell isolation, culture media and 
cell culture methods have major impact on the 
composition of MSC and their gene expression profiles 
[35-37]. Recently, we have compared gene expression 
changes in MSC from human bone marrow, which had 
been isolated in two different laboratories, grown in 
long-term culture with different culture media and 
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platforms [38]. Despite these differences there was a 
high resemblance in senescence-associated gene 
expression signatures. This led us to conclude, that 
these specific changes may be suitable for analysis of 
cellular aging. A matrix of distinctly up- and down-
regulated genes thus provides a robust method for 
quality control. Taken together, we found senescence-
associated up-regulation of the phosphate-associated 
RhoGAP protein-tyrosine (PARG1; alternatively termed 
ARHGAP29) and of the cyclin-dependent kinase-
inhibotor 2B (CDKN2B). Genes that were down-
regulated included pleiotrophin (PTN) and mini-
chromosome maintenance complex component 3 
(MCM3) (patent pending) [38]. Furthermore, work from 
other laboratories demonstrated that p16
ink4a is up-
regulated at higher passages. We now performed 
quantitative RT-PCR analysis of these five genes in five 
different types of MSC preparations and long-term 
cultures from different laboratories (Figure 2). Overall, 
there were related changes when comparing early and 
senescent passage. However, standard deviations were 
rather high in these analyses and it was not always 
possible to discern MSC in late passage. As microarray 
technology facilitates simultaneous analysis of 
thousands of genes, a larger panel of genes most likely 
yields a more robust predictor for quality control 
purposes. Further specification of senescence-associated 
markers and cross-validation in different MSC 
preparations may pave the way for a reliable quality 
control of cell preparations on gene expression level.  
 
Besides whole genome expression profiling, we could 
also demonstrate that DNA methylation profiles are 
clearly affected by long-term culture [2]. Using 
HumanMethylation27 BeadChip that represents 27,578 
CpG sites in more than 13,500 annotated genes, it was 
shown that specific promoter regions become either 
hyper- or hypo-methylated upon expansion of MSC. 
Some of these deviations were also differentially 
methylated in fibroblasts (unpublished data). Diploid 
cells have only two copies of DNA, whereas gene 
expression is based on multiple copies of mRNA. 
Therefore, distinction of methylation changes is a potent 
way to monitor cellular aging and this type of 
epigenetic analysis could be more suitable for 
accounting the heterogeneity within primary MSC 




Cellular therapies are currently tested for various novel 
therapeutic applications. At the same time requirements 
for quality control of cell products have to be specified 
and standardized. Establishing efficient quality control 
is challenging as it bases on trial and error to 
accumulate knowledge on optimal culture conditions for 
therapeutic applications. So far there are only limited 
numbers of reports available tracking side effects of 
clinical application of MSC. Notably, some of the 
preliminary observations are very promising [4,39]. It is 
yet unclear how many passages, population doublings 
or senescence-associated molecular changes are 
acceptable to grant optimal therapeutic effect for the 
different applications. Clearly, we need to establish a 
reliable method to track cellular aging of MSC. 
Molecular changes either on gene expression or DNA 
methylation levels provide powerful perspectives. 
Further bioinformatic analyses of datasets and 
validation enrolling different MSC preparations will 
pave the way for a reliable panel of distinct aging and 
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